NCT05676034

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Mar 3, 2023
Primary completion: Nov 30, 2024
Completion date: Dec 31, 2024
First posted: Jan 9, 2023
Last posted: Nov 22, 2023
Enrollment: 12
Arms / groups: 1 / —
Source: AACT · ctgov ingestion

Drugs studied

ursodeoxycholic acid
sodium phenylbutyrate

Indications studied

Wolfram Syndrome

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.

NCT05676034

Timeline

Sponsors

Drugs studied

Indications studied